LEO Pharma is among the world's leading companies in topical dermatology and parenteral treatment of thromboembolic disorders. We pride ourselves on the results that the dedicated and motivated people at LEO achieve. The creativity, knowledge and experience accumulated in our organisation together with our financial independence are pivotal to our aim of getting safe and efficacious drugs on the market.
Cialis, approved by the FDA in November 2003 for the treatment of erectile dysfunction, is the only oral ED treatment shown to improve erectile function up to 36 hours in most men. Cialis can be taken without regard to food. The absorption of Cialis is not reduced by food, including high-fat foods. Cialis is currently available in approximately 100 countries, including Australia, Brazil, Mexico, Canada, the United States and countries throughout Europe. More than 5 million patients worldwide have been treated with Cialis since its first introduction in February 2003. Cialis is available by prescription only and is not for everyone. Men taking nitrates, often used for chest pain, should not take Cialis. Such a combination could cause a sudden, unsafe drop in blood pressure. Men should discuss their medical conditions and medications, including alpha blockers for prostate problems or high blood pressure, with their doctors to ensure Cialis is right for them and that they are healthy enough for sexual activity. The most common side effects with Cialis were headache, upset stomach, delayed backache or muscle ache. As with any ED tablet, in the rare event of an erection lasting more than 4 hours (priapism), seek immediate medical attention to avoid long-term injury. Men should not drink alcohol in excess with Cialis. Cialis does not protect a man or his partner from sexually transmitted diseases, including HIV.
ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. With approximately 200 people employed in the Company's operations, ProStrakan is headquartered in Scotland with commercial operations throughout the rest of the UK and continental Europe. In R&D, the Company's Development group is located at Galashiels in Scotland. In June 2005, ProStrakan completed its initial public offering (IPO) of shares to become listed on the London Stock Exchange.
Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.
GW Pharmaceuticals was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines , including Sativex® Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications. GW's lead product, Sativex®, is approved and marketed in Canada for the relief of neuropathic pain in Multiple Sclerosis (MS) and also as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Each of these approvals was secured under the Notice of Compliance with Conditions (NOC/c) policy. Sativex® is also in late stage clinical development in Europe and the United States. GW has entered into three licensing agreements for Sativex® , with Bayer HealthCare in the UK and Canada, with Almirall in Europe (excluding UK) and with Otsuka Pharmaceutical Co.
American Oriental Bioengineering, Inc. (AOBO) is a fully integrated, pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products. A majority of its products are offered and derived from Chinese based traditional medicines and are manufactured using plant based materials. Its diversified business consists of prescription pharmaceutical products, over-the-counter (OTC) pharmaceutical products and nutraceutical products. Its pharmaceutical products have been approved by the Chinese State Food and Drug Administration (SFDA), based on demonstrated safety and efficacy. It sells its products primarily to hospitals, clinics, pharmacies and retail outlets at over 100,000 locations in all provinces, including rural areas and major cities in China. In October 2007, it completed the acquisition of Guangxi Boke Pharmaceutical Company Limited. (Source: 10-K)
http://www.shire-pharmaceuticals.com
Founded in 1986, Shire Pharmaceuticals Group plc is a rapidly growing international emerging pharmaceutical company with revenues for the full year 2002 of $1,037.3 million and an operating income of $327.038 million. The growth rates for revenues were 22% for 2002. Shire intends to grow both organically and by acquisition. The business development team at Shire focuses on the 'search' aspect of the Search and Development strategy. They are mainly involved in the acquisition of companies and in- and out-licensing of marketed products and development projects.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory